The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme-substrate interactions: Potential importance to its proposed anti-carcinogenic/carcinogenic actions

Carcinogenesis

Volumn 17, Issue 6, 1996, Pages 1357-1360

  Wiseman, Helen ^a   Lewis, David F V ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; DRUG METABOLISM; ENZYME SUBSTRATE COMPLEX; HUMAN; MOLECULAR MODEL; PRIORITY JOURNAL;

ANTICARCINOGENIC AGENTS; BINDING SITES; BIOTRANSFORMATION; CARCINOGENS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROXYLATION; ISOENZYMES; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; TAMOXIFEN;

EID: 0029935962     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Wiseman,H. (1994) Tamoxifen: Molecular Basis of Use in Cancer Treatment and Prevention. John Wiley & Sons, Chichester, UK.
2. 14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem. Pharmacol., 49, 1035-1042.
3. Shimada,T., Yamazaki,H., Mimura,M., Inui,Y. and Guengerich,F.P. (1994) Interindividual variation in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals. J. Pharmacol. Exp. Ther., 270, 414-423.
4. bm3). Xenobiotica, 25, 333-366.
5. Lewis,D.F.V. and Lake,B.G. (1995) Molecular modelling of members of the P4502A subfamily: application to studies of enzyme specificity. Xenobiotica, 25, 585-598.
6. Lake,B.G. and Lewis,D.F.V. (1996) The CYP4 family. In Ioannides,C. (ed.), Cytochromes P450: Metabolic and Toxicological Aspects. CRC Press, Boca Raton, FL.
7. Korzekwa,K.R. and Jones,J.P. (1993) Predicting the cytochrome P450 mediated metabolism of xenobiotics. Pharmacogenetics, 3, 1-18.
8. Smith,D.A. and Jones,B.C. (1992) Speculations on the substrate structure - -activity relationship (SSAR) of cytochrome P450 enzymes. Biochem. Pharmacol., 44, 2089-2098.
9. Price-Evans,D.A. (1993) Genetic Factors in Drug Therapy. Cambridge University Press, Cambridge, UK.
10. Gonzalez,F.J. and Gelboin,H.V. (1994) Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab. Rev., 26, 165-183.
11. White,I.N.H., Davies,A. Smith,L.L, Dawson,D. and De Matteis,F. (1993) Induction of CYP2B1 and 3A1, and associated monoxoygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. Biochem. Pharmacol., 45, 21-30.
12. Jacolot,F., Simon,J., Dreano,Y., Beaune,P., Riche,C. and Berthou,F. (1991) Identification of the cytochrome P450IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol., 41, 1911-1919.
13. Poon,G.K., Chui,Y.C., McCague,R., Lonning,E., Feng,R., Rowlands,M.G. and Jarman,M. (1993) Analysis of Phase I and Phase II metabolites of tamoxifen in breast cancer patients. Drug Metab. Dispos., 21, 1119-1124.
14. Mani,C., Gelboin,H.V., Park,S.S., Pearce,R., Parkinson,A. and Kupfer,D (1993) Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. Drug Metab. Dispos., 21, 645-656.
15. Blankson,E.A Ellis,S.W., Lennard,M.S., Tucker,G.T. and Rogers,K. (1991) The metabolism of tamoxifen by human liver microsomes is not mediated by cytochrome P450IID6. Biochem. Pharmacol., 42, 5209-5212.
16. Fisher,B., Costantino,J.P., Redmond,C.K., Fisher,E.R., Wickerham,D.L. and Cronin,W.M. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the national surgical adjuvant breast and bowel project (NSABP) B-14. J. Natl Cancer Inst., 86, 527-537.
17. Williams,M.L., Lennard,M.S., Martin,I.J. and Tucker,G.T. (1994) Interindividual variation in the isomerization of 4-hydroxy tamoxifen by human liver microsomes: involvment of cytochromes P450. Carcinogenesis, 15, 2733-2738.
18. Lewis,D.F.V., Parker,M.G. and King,R.J.B. (1995) Molecular modelling of the human estrogen receptor and ligand interactions based on site-directed mutagenesis and amino acid sequence homology. J. Steroid Biochem. Mol. Biol., 52, 55-65.
19. Raunio,H. and Pelkonen,O. (1995) Cancer genetics: genetic factors in the activation and inactivation of chemical carcinogens. In Ioannides.C. and Lewis,D.F.V. (eds), Drugs, Diet and Disease, Vol. I, Mechanistic Approaches to Cancer. Ellis Horwood, Chichester, UK, pp. 229-258.
20. Crespi,C.L., Penman,B.W., Gelboin,H.V. and Gonzalez,F.J. (1991) A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis, 12, 1197-1201.
21. King,C.M. (1995) Tamoxifen and the induction of cancer. Carcinogenesis, 16, 1449-1454.
22. Lewis,D.F.V. (1996) The Cytochromes P450: Structure, Function and Mechanism. Taylor and Francis, London, UK.
23. Ravichandran,K.G., Boddupalli,S.S., Haseman,C.A., Peterson,J.A. and Deisenhofer,J. (1993) Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450s. Science, 261, 731-736.
24. Degtyarenko,K.N. and Archakov,A.I. (1993) Molecular evolution of the P450 superfamily and P450-containing mono-oxygenase systems. FEBS Lett., 332, 1-8.
25. Lewis,D.F.V., Eddershaw,P.J., Goldfarb,P.S. and Tarbit,M.H. (1996) Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. Xenobiotica, submitted for publication.
26. Hsu,M.-H, Griffin,K.J., Wang,Y., Kemper,B. and Johnson,E.F. (1993) A single amino acid substitution confers progesterone 6β-hydroxylase activity to rabbit cytochrome P4502C3. J. Biol. Chem., 268, 6939-6944.
27. Richardson,T.H. and Johnson,E.F. (1994) Alteration of the regiospecificity of progesterone metabolism by the mutagenesis of two key amino acid residues in rabbit cytochrome P4502C3v. J. Biol. Chem., 269, 23937-23943.
28. Islam,S.A., Wolf,C.R., Lennard,M.S. and Sternberg,M.J.E. (1991) A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis, 12, 2211-2219.
29. Lewis,D.F.V. (1995) The cytochromes P450: ubiquitous enzymes of metabolism. Mfg Chemist, 66, 35-37.
30. Lewis,D.F.V., Eddershaw,P.J., Goldfarb,P.S. and Tarbit,M.H. (1996) Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific 2D6 substrate metabolism. Xenobiotica, submitted for publication.
31. Coh substrate specificity by mutation of a single amino-acid residue. Nature, 339, 632-634.
32. cam: T185F mutant increases coupling and abolishes 3-hydroxynor camphor product. Protein Sci., 2, 357-365.
33. cam to increase the stereospecificity and coupling of aliphatic hydroxylation. Protein Eng., 6, 207-212.